



Hunan Huateng Pharmaceutical Co Ltd

One-stop CDMO to meet your needs for pharmaceutical molecules



CONTENTS

Hunan Huateng Pharmaceutical Co. Ltd.

- Company Overview
- R&D and Analytical Capability
- Production Capability
- Business Segments
- Professional Services

1. Company Overview



Hunan Huateng Pharmaceutical Co. Ltd.

Founded Date: August, 2013

Address: Headquarter - Building E1, Lugu Corporation Plaza, High-

Tech Industrial Development Zone, Changsha City, Hunan Province,

P.R.China

Manufacturing Site - Huacheng Rd, Tongguan Circular Economy Industrial Base, Wangcheng Economic Development Zone, Changsha

City, Hunan Province, P.R.China

Business Segments: PEG derivatives and research chemical reagents;

CDMO for pharmaceutical intermediates & APIs.

Employees: 400+ full time staff

Financial status: Complete Series A, Series B and Series C Funding



2013

2016

2020

2021

Officially operated in Changsha

Launched Fisrt R&D Center

Factory was completed and put into production

Set up Biopharma PEG in USA












Certification


- ISO 9001 issued;
- EXCIPACT GMP Certificate;
- ISO14000, and OHSAS18000 certifications are under approval;







2. Excellent R&D and Analytical Capability





Expeienced R&D Team

Highly Experienced Team

400+ employee and 160+ highly experienced scientists and process engineers.



Drug Research Institute

R&D of chemical generics, longacting targeted innovative drugs & biological drugs.



Industrial Technology Research Institute

R&D of PEGylated peptides and protein-based drugs, new class 1 target drugs, the Green manufacturing of specialty APIs.





Advanced Analytical Equipment











Gel Chromatograph



400 MHz NMR system GC/MS HPLC Infrared analyzer

3. Production Capabilities



Analytical Equipment List

| No | Name of Equipment | Quantity |
|----|-----------------------------------|----------|
| 1 | KF Karl Fischer Moisture Analyzer | 2 |
| 2 | NMR | 1 |
| 3 | Coulomb Moisture Meter | 1 |
| 4 | Melting point apparatus | 2 |
| 5 | Polarimeter | 2 |
| 6 | GPC/RI | 1 |
| 7 | HPLC | 6 |
| 8 | HPLC/UV | 7 |
| 9 | HPLC/CAD | 2 |
| 10 | HPLC/ELSD | 2 |
| 11 | HPLC/GPC-IC | 1 |
| 12 | LC/MS | 1 |
| 13 | GC/FID | 5 |
| 14 | GC/MS | 1 |
| 15 | Moisture Meter | 2 |
| 16 | Fourier NIR Spectrometer | 1 |
| 17 | Colorimeter | 1 |

| No | Name of Equipment | Quantity |
|----|--|----------|
| 1 | UV-visible spectrophotometer | 2 |
| 2 | 2.83L Dust particle counter | 1 |
| 3 | Conductivity meter | 2 |
| 4 | Planktonic bacteria collector | 1 |
| 5 | Vertical Sterilizer | 1 |
| 6 | Mildew incubator | 2 |
| 7 | Biochemical incubator | 3 |
| 8 | Biological safety cabinet | 1 |
| 9 | Microbial limit tester | 2 |
| 10 | Entotoxin Detector | 1 |
| 11 | Drug Stability Test Chamber | 2 |
| 12 | Electro-heating standing-temperature incubator | 1 |
| 13 | electronic balance/0.01g | 6 |
| 14 | electronic balance/0.001g | 1 |
| 15 | electronic balance/0.0001g | 2 |
| 16 | electronic balance/0.00001g | 1 |
| 17 | pH meter | 2 |



60+ Granted Patents, 50+ Patents Under Application








3. Strong Production Capability

800+ Sets of Advanced Equipment



Perfect QA & QC Management System

Independent Manufacturing Site

Comprehensive EHS System

3. Production Capabilities







Manufacturing Site

Address: Tongguan Circular Economy Industrial Base, Wangcheng Economic Development Zone, Changsha, Hunan, P.R.China

Area: 34,000m², putting into operation since August, 2020. Four production workshops with a total of 20,000m².

Capacity: lab scale to pilot plant to full-scale production of PEG Derivatives, APIs and intermediates and other chemical reagents.

Annual Output Value: RMB 1 billion.



800+ Sets of Advanced Equipment














3. Production Capabilities



Intelligent Production System





System control center



DCS & SIS control console

Distributed Control System (DCS) main interface



DCS & SIS system equipment room

Safety Instrumented System (SIS) main interface



| No | Name of Equipment | Capacity | Quantity |
|----|---|----------|----------|
| 1 | Hydrogenation Reactor | 2000L | 2 |
| 2 | Amination Reactor | 2000L | 1 |
| 3 | Liquid Nitrogen Low Temperature Reactor | 2000L | 4 |
| 4 | Stainless Steel Reactor | 1000L | 1 |
| 5 | Stainless Steel Reactor | 2000L | 2 |
| 6 | Stainless Steel Reactor | 3000L | 1 |
| 7 | Stainless Steel Reactor | 5000L | 12 |
| 8 | Enamel Reactor | 500L | 2 |
| 9 | Enamel Reactor | 2000L | 21 |
| 10 | Enamel Reactor | 3000L | 31 |
| 11 | Enamel Reactor | 5000L | 92 |
| 12 | Pilot Plant Enamel Reactor | 200L | 2 |
| 13 | Pilot Plant Enamel Reactor | 300L | 3 |
| 14 | Pilot Plant Enamel Reactor | 500L | 4 |



| No | Name of Equipment | Capacity | Quantity |
|----|--------------------------------------|------------|----------|
| 1 | Pilot Plant Stainless Steel Reactor | 500L | 1 |
| 2 | Pilot Plant Enamel Reactor | 1000L | 4 |
| 3 | Pilot Plant Stainless Steel Reactor | 1000L | 1 |
| 4 | Pilot Plant Double Cone Vacuum Dryer | 1000L | 2 |
| 5 | Pilot Plant Centrifuge | 600 | 2 |
| 6 | Enamel Rectifying Still | 300L | 2 |
| 7 | Enamel Rectifying Tower | φ200*10000 | 2 |
| 8 | Enamel Rectifying Still | 5000L | 4 |
| 9 | Stainless Steel Rectifying Tower | φ400*10000 | 2 |
| 10 | Enamel Rectifying Tower | φ400*10000 | 2 |
| 11 | Enamel Rectifying Still | 2000L | 1 |
| 12 | Enamel Rectifying Tower | φ400*10000 | 1 |
| 13 | Stainless Steel Rectifying Still | 3000L | 1 |
| 14 | Stainless Steel Rectifying Tower | φ400*10000 | 1 |



| No | Name of Equipment | Capacity | Quantity |
|----|--|---------------|----------|
| 1 | Double Cone Vacuum Dryer | 2000L | 12 |
| 2 | Double Cone Vacuum Dryer | 3000L | 2 |
| 3 | Top Discharge Centrifuge | 800 | 1 |
| 4 | Top Discharge Centrifuge | 1250 | 2 |
| 5 | Top Discharge Centrifuge | 1250 | 1 |
| 6 | Flat Plate Bottom Discharge Centrifuge | LGZ1250NF/303 | 6 |
| 7 | Flat Plate Bottom Discharge Centrifuge | LGZ1249HF | 4 |
| 8 | Decanter Centrifuge | 450 | 2 |
| 9 | Decolorization Reactor | 2000L | 1 |
| 10 | Decolorization Reactor | 500L | 1 |
| 11 | Clean Room Crystallization Reactor | 2000L | 1 |
| 12 | Clean Room Crystallization Reactor | 500L | 1 |
| 13 | Clean Room Double Cone Vacuum Dryer | 1000L | 1 |
| 14 | Clean Room Centrifuge | 600 | 1 |



| No | Name of Equipment | Capacity | Quantity |
|----|---|------------------|----------|
| 1 | 7℃ Water Chiller | MCW1100 | 1 |
| 2 | 7℃ Water Chiller | MCW7200 | 1 |
| 3 | 7°C Water Chiller | 490Kw | 1 |
| 4 | 7°C Water Chiller | 720KW | 1 |
| 5 | -15℃ Evaporative Water-Cooled Screw Chiller | 980KW | 3 |
| 6 | Dual Stage Falling Film Evaporators | 20m2 (φ400*3100) | 3 |
| 7 | Exhaust Gas Treatment Spray Tower | φ1200*5000 | 8 |
| 8 | Cooling Tower | 450m3/h | 4 |
| 9 | PM Inverter Screw Air Compressor | SL75 | 2 |
| 10 | Power Frequency Screw Air Compressor | IRN75 | 1 |
| 11 | Nitrogen Generator | BPN/TYN-300-99 | 2 |
| 12 | RTO | 15000m3/h | 1 |
| 13 | Wastewater Treatment | 500m3/d | 1 |



High Standard Warehouse Storage

- 2 Class A warehouses of 750m²
- 1 class C warehouse of 3600m²
- 12 storage tanks of 50m³
- Cold storage for PEG derivatives.
 Our PEG derivatives are thoroughly dried and packaged under an inert atmosphere at or below -5° C.









3. Production Capabilities



EHS System

Huateng Pharma is dedicated to be an environment friendly manufacturer!

- Improve the development and upgrade of the production process by introducing high-tech means. Effectively improve the reaction efficiency in the production process, and reduce energy loss and waste emission from the source.
- Improve the operating skills of front-line workers through comprehensive training. Improve the technical level of energy management. Increase the investment in environmental protection equipment and facilities, and establish a sewage treatment station.
- Conduct daily environmental monitoring work to check and track the operation of environmental protection facilities, and strictly achieve the emission standards.



Wastewater Treatment - TIC Anaerobic Reactor




Acid Waste Gas Treatment - Falling Film
Absorption + Alkali Absorption



Organic Waste Gas Treatment – RTO (Regenerative Thermal Oxidizer)



Perfect QA & QC Management System



Strengthen supplier screening and control mechanism

Standardize site operation management

Strictly follow SOP standard operating procedures

Dividing storage space and substorage in accordance with national norms and standards





4. Business Segments







- 5000+ monodispersed and polydispersed PEG derivatives with molecular weights ranging from 200 to 4w.
- Multifunctional groups covers active esters, maleimides, sulfhydryl, amino, azide, phospholipids, fluorescein, etc.
- Intergrated production line and quality management system from PEGs raw materials production, trial production, pilot production and GMP commercial supplying.


















^{*}PEGs have been shown to provide improved water solubility and biocompatibility in drugs and other applications. And PEG derivatives provide the ability to attach a variety of reactive functional groups to the terminal positions of these polymers has greatly increased their applications.

PEGylation

Significant pharmacological advantages of PEGylated peptides, proteins, and antibody fragments:

- 1) Improved drug solubility
- 4) extended circulating life
- 2) reduced dosage frequency
- 5) increased drug stability
- 3) potentially reduced toxicity
- 6) enhanced protection from proteolytic degradation



mPEG-SC

Side Chain of Anti-Diabetic Drug MW:1K,2K,3K;5K,10K;20K;30K

mPEG-pALD

Side Chain of Nervous System Drug MW:1K,2K,3K;5K,10K;20K;30K

mPEG-Succinimidyl Propionate

Side Chain of Hematological System Drug MW:1K,2K,3K;5K,10K;20K;30K

Fmoc-NH-PEG4-CH2CH2COOH

CAS No.: 557756-85-1

mPEG-Mal

Side Chain of Anti-Diabetic Drug MW:1K,2K,3K;5K,10K;20K;30K

$$\rightarrow 0$$

Boc-NH-PEG3-CH2COOH

CAS No.: 462100-06-7

PEG Linker for ADC Drugs

Water solubility, lack of toxicity; low immunogenicity and well-defined chain lengths and molecular weights are specific characteristics of PEG moieties relevant to ADC development.

mPEG36-NH2 CAS No: 32130-27-1

Mal-NH-PEG8-COOH CAS No.: 1334177-86-4

N-(Azido-PEG3)-N-bis(PEG3-t-butyl ester)
CAS No: 2055042-56-1

PEG Moiety for PROTAC Linker

PROTAC linker is a crosslinker that connects two functional motifs of a PROTAC, a target protein binder and an E3 ligase recruiter.

$$H_2N$$
 O H

NH2-PEG4-OH CAS No.: 86770-74-3

$$N_3$$
 O_6

N3-PEG6-OH CAS No: 86770-69-6

Boc-NH-PEG3-Tos CAS No: 1246999-33-6


$$\begin{array}{c} \begin{array}{c} \\ \\ \end{array} \end{array}$$

Boc-NH-PEG11-N3 CAS No.: 2395004-21-2



LNPs Delivery System Excipients

Lipid Nanoparticles (LNPs) are delivery systems commonly employed in the field of nucleic acid drugs. The LNP technology has been adopted for COVID-19 vaccine manufacture.



DSPE-PEG-NH2

CAS NO.: 474922-26-4

mPEG-DSPE

CAS NO.: 147867-65-0

DSPE-PEG-Mannose

PEG Hydrogels for Medical Devices

PEG Derivatives

Multi-arm PEG derivatives are mostly employed in the formation of hydrogels for controlled release of therapeutics; for use in medical devices; regenerative medicine; and in various other applications, including cell culture, wound sealing, and wound healing.

$$C - \left\{ CH_{2} - O - \left(CH_{2}CH_{2}O \right)_{n} CH_{2}CH_{2} - O - C - CH_{2}CH_{2}CH_{2} - C - O - N \right\}_{4}$$

$$C - \left\{ CH_{2} - O - \left(CH_{2}CH_{2}O \right)_{n} CH_{2}CH_{2} - O - C - CH_{2}CH_{2} - C - O - N \right\}_{4}$$

4-ArmPEG-SG

4-ArmPEG-SS

8-ArmPEG-SS

3D Printing

3D printing biomaterials require biocompatibility, porosity, biodegradability and good adhesion. PEG hydrogels meet these specifications, and in particular PEG acrylate (PEG-ACLT) derivatives are widely applied in hydrogel formation via photopolymerization.



Dye Labeling

The PEG chains alter tissue biodistribution, allowing brighter liver metastases labeling and decreased accumulation in normal organs, particularly the liver.

Application:

- ①Cell Labeling
- ②Tissue Imaging
- ③Tumor Identification

Fluorescein

Fluorescein labeling

FITC-PEG-R

R=OH,SH,CHO,NH2,NCO,N3,Mal,Alkyne,AC,ACA,MA,Silane,GA,SA,GAA,SAA,AA,IA,EP,Mal,SC,SCM,SPA,SG,SS,GAS,SAS,CDI,NPC,OPSS,Ts,LA,Biotin,DSPE,DMPE,CLS etc

Cyanine

Cyanine Labeling

Rhodamine labeling

Cy-PEG-R

R=OH,SH,CHO,NH2,NCO,N3,Mal,Alkyne,AC,ACA,MA,Silane,GA,SA,GAA,SAA,AA,IA, EP,Mal,SC,SCM,SPA,SG,SS,GAS,SAS, CDI,NPC.OPSS.Ts.LA.Biotin.DSPE.DMPE,CLS etc

CY5.5-PEG-SH

mPEG-FITC

RB-PEG-Mal

Rhodamine

RB-PEG-R

R=OH,SH,CHO,NH2,NCO,N3,Mal,Alkyne,AC,ACA,MA,Silane,GA,SA,GAA,SAA,AA,IA, EP,Mal,SC,SCM,SPA,SG,SS,GAS,SAS, CDI,NPC,OPSS,Ts,LA,Biotin,DSPE,DMPE,CLS etc

PEG Raw Materials

PEG Derivatives

Huateng Pharma manufactures linear and multi-arm polyethylene glycol (PEG) raw materials with high purity and low polydispersity.

O(O) OH

mPEG-OH

MW:1K,2K,5K,10K;20K

 $C = \left[CH_2 - O - \left(CH_2CH_2O\right)_n CH_2CH_2 - OH\right]_4$

4-ArmPEG-OH

MW:2K,5K,10K;20K

Trt-PEG-OH MW: 2K,5K

$$HO$$
 OH OH

OH-PEG-OH

MW:400,1K,1.2K,6K,10K



Featured Monodisperse PEGs

- Ultra high purity, large in stock
- Great water solubility

- A broad selection of functional groups
- From lab to GMP commercial scale

| CAS No. | Name |
|--------------|-----------------|
| 2395004-21-2 | Boc-NH-PEG11-N3 |
| 1246999-33-6 | Boc-NH-PEG3-Tos |
| 756525-99-2 | Mal-NH-PEG4-NHS |
| 32130-27-1 | mPEG36-NH2 |
| 1800414-71-4 | N3-PEG11-NH2 |
| 1056024-94-2 | N3-PEG3-COOH |
| 1245718-89-1 | N3-PEG3-SPA |

| CAS No. | Name |
|--------------|----------------|
| 86770-69-6 | N3-PEG6-OH |
| 6338-55-2 | NH2-PEG3-OH |
| 86770-74-3 | NH2-PEG4-OH |
| 77544-68-4 | OH-PEG3-Tos |
| 77544-60-6 | OH-PEG4-Tos |
| 3386-18-3 | OH-PEG9-OH |
| 1818294-30-2 | Trityl-PEG7-N3 |



Featured Polydispersed PEGs

- Ultra high purity, large in stock
- Great water solubility

- A broad selection of functional groups
- From lab to GMP commercial scale

| Name | M.W. |
|------------------|--------------------------|
| Biotin-PEG-SH | 1K,2K,3.4K,5K,10K,20K |
| Bn2-PEG-OH | 1K,2K,3.4K,5K |
| DSPE-PEG-Mal | 1K,2K,3.4K,5K,10K,20K |
| DSPE-PEG-Mannose | 1K,2K,3.4K,5K,10K,20K |
| DSPE-PEG-NH2 | 1K,2K,3.4K,5K,10K,20K |
| HZ-PEG-HZ | 1K,2K,3.4K,5K,10K,20K |
| mPEG-AA | 1K,2K,5K,10K,20K |
| mPEG-DSPE | 1K,2K,3.4K,4K,5K,10K,20K |

| Name | M.W. |
|------------|-----------------------------|
| mPEG-EPO | 1K,2K,5K,10K,20K |
| mPEG-N3 | 1K,2K,3.4K,5K,10K,20K |
| mPEG-NH2 | 1K,2K,3K,3.4K,4K,5K,10K,20K |
| mPEG-NHS | 1K,2K,3.4K,5K,10K,20K |
| mPEG-SH | 1K,2K,5K,10K,20K |
| mPEG-SPA | 1K,2K,3.4K,5K,10K,20K |
| OH-PEG-AA | 1K,2K,5K,10K,20K |
| SH-PEG-NH2 | 1K,2K,3.4K,5K,10K,20K |



Featured Multi-Arm PEGs

- Ultra high purity, large in stock
- Great water solubility

- A broad selection of functional groups
- From lab to GMP commercial scale

| Name | M.W. |
|---------------|------------------|
| 4-ArmPEG-AC | 2K, 5K, 10K, 20K |
| 4-ArmPEG-CHO | 2K, 5K, 10K, 20K |
| 4-ArmPEG-DBCO | 2K, 5K, 10K, 20K |
| 4-ArmPEG-Mal | 2K, 5K, 10K, 20K |
| 4-ArmPEG-NH2 | 2K, 5K, 10K, 20K |
| 4-ArmPEG-SC | 2K, 5K, 10K, 20K |
| 4-ArmPEG-SH | 2K, 5K, 10K, 20K |

| Name | M.W. |
|-----------------|---------------|
| 8-ArmPEG-AlKyne | 10K, 20K, 40K |
| 8-ArmPEG-DBCO | 20K, 40K |
| 8-ArmPEG-EPO | 10K, 20K, 40K |
| 8-ArmPEG-Mal | 10K, 20K, 40K |
| 8-ArmPEG-N3 | 10K, 20K, 40K |
| 8-ArmPEG-NH2 | 10K, 20K, 40K |
| 8-ArmPEG-SH | 10K, 20K, 40K |

4. Business Segments





Pharmaceutical Intermediates

Huateng Pharma is able to provide the services of various kinds of API intermediates' process development and scale-up production with capacities varying from gram to kilograms and multi tons. We have specialized facilities for high-temperature and high-pressure reactions as well as low-temperature continuous-flow reactions, enabling us to produce a wide range of customer-oriented products with high cost performance.



Anti-Diabetic Drug Intermediates

| No. | CAS No. | Product Name | End Use | |
|-----|--|---|---------------------------------|--|
| 1 | 898566-17-1 | 2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene | Canagliflozin | |
| 2 | 1030825-20-7 | | | |
| 3 | 1103738-29-9 | 4-lodo-1-chloro-2-(4-ethoxybenzyl)benzene | Dapagliflozin | |
| 4 | 461432-23-5 | 5-bromo-2-chloro-4'-ethoxydiphenylmethane | Dapagiiiioziii | |
| 5 | 915095-89-5 | (3S)-3-[4-[(5-bromo-2-chlorophenyl)methyl]phenoxy]oxolane | henoxy]oxolane Empagliflozin | |
| 6 | 915095-94-2 | (S)-4-iodo-1-chloro-2-(4-tetrahydrofuran-3-y loxy-benzyl)-benzene | | |
| 7 | 203787-91-1 | 1662688-20-1 Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH | | |
| 8 | 1662688-20-1 | | | |
| 9 | 1118767-16-0 Octa(OtBu)-Glu(AEEA-AEEA-OH)-OtBu | | Semaglutide | |
| 10 | 1143516-05-5 | 16-05-5 AEEA-AEEA | | |



Anti-Cancer Drug Intermediates

| No. | CAS No. | Product Name | End Use | |
|-----|--------------|--|-------------|--|
| 1 | 53617-35-9 | 4-Morpholino piperidine | مانورند | |
| 2 | 1256584-73-2 | 2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid | Alectinib | |
| 3 | 247068-85-5 | (2S)-2-Amino-4-methyl-1-[(2R)-2-methyloxiranyl]-1-pentanone trifluoroacetate | | |
| 4 | 247068-82-2 | Boc-L-leucine epoxyketone | Carfilzomib | |
| 5 | 868539-96-2 | Boc-HPh-Leu-Phe-OMe | | |
| 6 | 50890-83-0 | 1-Methylindazole-3-carboxylic acid | Granisetron | |
| 7 | 36082-50-5 | 5-Bromo-2,4-dichloropyrimidine | | |
| 8 | 733039-20-8 | 5-Bromo-2-chloro-N-cyclopentylpyrimidin-4-amine | Palbociclib | |
| 9 | 571188-59-5 | 1-Boc-4-(6-aminopyridin-3-yl)piperazine | | |



Cardiovascular Agent Intermediates

| No. | CAS No. | Product Name | End Use |
|-----|--------------|---|-----------|
| 1 | 14064-10-9 | Diethyl chloromalonate | Bosentan |
| 2 | 365998-36-3 | Edoxaban Impurity 47 | Edoxaban |
| 3 | 1210348-34-7 | Ethanediamide impurity A | |
| 4 | 505-66-8 | Homopiperazine | Fasudil |
| 5 | 27655-40-9 | 5-ISOQUINOLINESULFONIC ACID MONOHYDRATE | |
| 6 | 156-83-2 | 2,4-Diamino-6-chloropyrimidine | Minoxidil |
| 7 | 946-99-6 | Methyl-3-(4-bromomethyl)cinnamate | |
| 8 | 20511-20-0 | Ethyl 4-methylcinnamate | Ozagrel |
| 9 | 475085-57-5 | MRE-269 | Selexipag |
| 10 | 42042-71-7 | 4-(propan-2-ylamino)butan-1-ol | |



Other Intermediates

| No. | CAS No. | Product Name | End Use | |
|-----|--------------|--|------------|--|
| 1 | 16490-02-1 | 4,6-Pyrimidine dicarboxylic acid | Brilacidin | |
| 2 | 1902955-29-6 | methyl 5-(2,4-difluorophenyl)-4-methoxy-1H-pyrrole-3-carboxylate | Fexuprazan | |
| 3 | 111128-12-2 | 2-(4-Bromomethyl-phenyl)-propionic acid | | |
| 4 | 492-37-5 | DL-2-Phenylpropionic acid | Loxoprofen | |
| 5 | 619-14-7 | 3-Hydroxy-4-nitrobenzoic acid | Tafamidis | |
| 6 | 2374-03-0 | 4-Amino-3-hydroxybenzoic acid | | |
| 7 | 1282518-60-8 | 1-Isopropyl-1H-pyrazole-5-boronic acid,pinacol ester | Voxelotor | |
| 8 | 881674-56-2 | 5-(2-Fluorophenyl)-1H-pyrrole-3-carbaldehyde | | |
| 9 | 16133-25-8 | pyridine-3-sulfonyl chloride | Vonoprazan | |





Fine & Specialty Chemicals

| No. | CAS No. | Product Name | Structure |
|-----|------------|-------------------------------------|-------------------------|
| 1 | 36062-04-1 | Tetrahydrocurcumin | но |
| 2 | 82257-09-8 | APS-5 | |
| 3 | 2743-38-6 | Dibenzoyl-L-tartaric acid | HO YOUNG |
| 4 | 593-56-6 | O-Methylhydroxylamine hydrochloride | HCI ONH ₂ |
| 5 | 6358-06-1 | 2-Chloro-5-aminophenol | H ₂ N OH |
| 6 | 41731-23-1 | 2-Bromo-5-methylthiazole | S Br |

Fine & Specialty Chemicals

| No. | CAS No. | Product Name | Structure |
|-----|------------|-------------------------------|------------------------------|
| 1 | 32316-92-0 | 2-Naphthaleneboronic acid | OH B OH |
| 2 | 372-19-0 | 3-Fluoroaniline | H ₂ N F |
| 3 | 17325-26-7 | Methyl 4-imidazolecarboxylate | HN |
| 4 | 84459-33-6 | 2-Bromo-4-chlorobenzaldehyde | O CI |
| 5 | 6099-90-7 | Phloroglucinol dihydrate | HO OH H ₂ O OH OH |
| 6 | 3096-70-6 | 4-Amino-3,5-xylenol | HO NH ₂ |



5. Professional Services



5. Professional Services




CDMO/CMO Services

In order to better serve customers, we have built a CDMO technology platform, equipped with professional R&D, production and QC teams, established a pilot and scale-up production workshop that meets GMP standards.

We are able to provide:

- > Customized R&D and production of intermediates and other chemicals ranging from grams to tons
- > Process optimization and rapid scale-up of intermediates and other chemicals of existing synthetic processes
- > Development of a more environmentally safe production process



Product Life Cycle Management -Continuous Cost Improvement, Sustainable Capacity.



Custom Synthesis

Our Chemical Synthesis Capabilities

- (1) Various small molecule compounds
- (2) PEG derivatives with various functional group
- (3) Medicinal chemistry and drug discovery
- (4) Organometallic chemistry

- (5) Heterocyclic chemistry
- (6) Special reagents
- (7) Scale-up production
- (8) Academic exploration cooperation









Thank You!

Email: <u>sales@huatengusa.com</u> Telephone: +86 731 89916275 Fax: +86 0731-82251112-818 Website: https://us.huatengsci.com